Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
William Hawkins
Washington University, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Accuronix Therapeutics
Other : Licensing Agreement/Intellectual property rights from the awardee institution
Based on WU’s Research COI Policy and the Procedures for Determining and Managing Research Financial Conflicts of Interests, the CIRC determined Dr. Hawkins personal financial relationship with Accuronix Therapeutics creates a financial conflict of interest due to the following reasons:
• His personal financial relationship with Accuronix Therapeutics is directly related to the NIH sponsored research because he has an ownership interest in the company and the research is evaluating a technology he co-invented, which is being licensed to Accuronix Therapeutics
• The primary focus of Accuronix Therapeutics is to commercialize the IP being developed and evaluated in the above mentioned research
• The outcomes of the research could directly benefit Accuronix Therapeutics
• As an inventor of the technology, Dr. Hawkins would be entitled to future royalties when the license agreement with Accuronix is executed
• His role as PI of the NIH grant will directly affect all aspects of the research
While the CIRC determined Dr. Hawkins has a financial conflict of interest related to the NIH grant, it concluded sufficient mechanisms exist to ensure the objectivity and integrity of the research and adequate protections are in place for the human research participants of the corresponding human study, based on the following reasons:
• The research is basic in nature and in its early stages
• His only role in the human study is to help recruit potential participants and will not be involved in the consenting of participants
• There is no increase in risk to the human research participants because their only involvement is to provide tumor samples for in vitro and in vivo testing
• Additionally, a plan has been developed to mitigate his financial conflict of interest related to the NIH grant, which is outlined below
SIGMA-2/PEPTIDOMIMETIC CONJUGATES TARGET APOPTOSIS IN PANCREATIC CANCER
Pancreatic adenocarcinoma is the fourth most lethal cancer and notoriously resistant to standard chemotherapy. We present here a novel strategy for delivery of small molecules selectively to pancreatic cancer that induce tumor cell death. We propose the rational design and functional validation of several candidate compounds in vitro and in a mouse model of human pancreatic cancer.
Filed on September 01, 2016.
Tell us what you know about William Hawkins's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
William Hawkins filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| William Hawkins | Washington University | Conflict of Interest | Accuronix Therapeutics | Value cannot be readily determined |
| William Hawkins | Washington University | Conflict of Interest | Accuronix Therapeutics | Value cannot be readily determined |
| William Hawkins | Washington University | Conflict of Interest | Accuronix Therapeutics | Value cannot be readily determined |
| William Hawkins | Washington University | Conflict of Interest | Accuronix Therapeutics | Value cannot be readily determined |
| William Hawkins | Washington University | Conflict of Interest | Accuronix Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.